FLT3 and acute myeloid leukemia: AML‐01 and AML‐02 are representative of patients with adverse prognosis (i.e., patients carrying DNMT3A, NPM1, and FLT3 mutations; Appendix Fig S4A), but show different in vivo disease aggressiveness and lentiviral transduction efficiency (30% and 98%, respectively; Appendix Fig S4B).